indazoles has been researched along with Carcinoma, Non-Small Cell Lung in 104 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (2.88) | 18.7374 |
| 1990's | 14 (13.46) | 18.2507 |
| 2000's | 3 (2.88) | 29.6817 |
| 2010's | 53 (50.96) | 24.3611 |
| 2020's | 31 (29.81) | 2.80 |
| Authors | Studies |
|---|---|
| Awad, MM; Dowlati, A; Dy, GK; Haque, B; Iannotti, N; Iyer Singh, N; Lu, S; Ramalingam, SS; Spigel, DR; Stinchcombe, TE; Tang, Y; Teslenko, I; Thara, E | 1 |
| Byun, JH; Cho, HJ; Choi, E; Han, DG; Jung, IH; Park, T; Seo, SW; Yoon, IS | 1 |
| Djebli, N; González-Sales, M; Jaminion, F; Meneses-Lorente, G; Mercier, F | 1 |
| Ahn, MJ; Bazhenova, L; Chawla, SP; Chen, D; Chiu, CH; Cho, BC; De Braud, F; Demetri, GD; Drilon, A; Dziadziuszko, R; Fakih, M; Goto, K; Heinzmann, S; John, T; Lee, J; Lin, JJ; Liu, SV; Patel, MR; Pitcher, B; Rolfo, C; Seto, T; Siena, S; Wilson, TR | 1 |
| Bartolome, L; Camidge, DR; Cappelleri, JC; Daniele, P; Groff, M; Iadeluca, L; Tremblay, G; Usari, T; Wilner, K; Wiltshire, R | 1 |
| Barlesi, F; Chang, CW; Choeurng, V; Dennis, L; Doebele, RC; Drilon, A; Dziadziuszko, R; Hung, T; Li, M; Riehl, T; Simmons, B; Skoletsky, J; Wang, K; Wilson, TR; Woodhouse, R; Wu, C | 1 |
| Cui, Y; Du, F; Feng, L; Huang, W; Li, B; Yin, X | 1 |
| Abdelbaki, MS; Armstrong, AE; Basu, EM; Bergthold, G; Cardenas, A; Caron, H; Cash, T; Chohan, S; Chow Maneval, E; Corradini, N; Desai, AV; Devlin, C; Farid-Kapadia, M; Foster, JH; Fox, E; Gajjar, A; Gauvain, K; Hutchinson, KE; Macy, ME; Maese, L; Marshall, LV; Meneses-Lorente, G; Pratilas, CA; Robinson, GW; Sabnis, AJ; Shusterman, S; Weiss, BD; Whipple, NS; Yoon, J | 1 |
| Chen, L; Jiang, Q; Li, H; Li, M | 1 |
| Mahapatra, M; Mal, S; Malik, U; Mishra, A; Paidesetty, SK; Pal, D | 1 |
| Fujita, N; Gong, B; Hanzawa, H; Hata, AN; Isoyama, T; Iwasaki, S; Kagoshima, Y; Kamai, Y; Katayama, R; Kiga, M; Koike, S; Miyamoto, M; Nakao, N; Nishio, M; Oh-Hara, T; Seto, Y; Shaw, AT; Shimizu, Y; Takeda, Y; Togashi, N; Tominaga, Y; Watanabe, K; Yanagitani, N; Yoda, S | 1 |
| Lassen, U | 1 |
| Ahn, MJ; Arkenau, HT; Barlesi, F; Chae, YK; Chiu, CH; Cho, BC; Chow-Maneval, E; Chung, CH; Cui, N; de Braud, F; Doebele, RC; Drilon, A; Dziadziuszko, R; Eng, S; Goto, K; John, T; Johnson, A; Karapetis, CS; Kim, SW; Krebs, MG; Li, YC; Lin, CC; Murakami, H; Ohe, Y; Otterson, GA; Patel, MR; Prenen, H; Riehl, T; Rolfo, C; Seto, T; Shaw, AT; Siena, S; Simmons, B; Tan, DSW; Wilson, TR; Wolf, J | 1 |
| Hu, H; Hu, MN; Li, JY; Miao, XK; Mou, LY; Xu, JJ; Yang, WL; Zhang, JY; Zhang, XW; Zhou, TX | 1 |
| Cerea, G; Marrapese, G; Pizzutilo, EG; Sartore-Bianchi, A; Siena, S; Tosi, F | 1 |
| Carlson, JJ; Roth, JA; Sullivan, SD; Williamson, T; Xia, F | 1 |
| Adhikary, R; Hussain, T; Khandelwal, R; Nayarisseri, A; Singh, SK | 1 |
| Ahn, JS; Ahn, MJ; Jung, HA; Lee, J; Lee, SH; Park, K; Park, S; Sun, JM | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Arizio, F; Bironzo, P; Listì, A; Novello, S; Passiglia, F; Righi, L; Scagliotti, GV; Volante, M | 1 |
| Chen, Y; Huang, K; Huang, Y; Li, Y; Liu, X; Petersen, RB; Quan, C; Wang, Q; Wang, X; Yang, D; Zheng, L | 1 |
| Chen, C; Chen, J; Gong, H; Li, W; Li, Y; Liu, C; Liu, H; Liu, M; Shi, R; Yuan, Y; Zhang, H; Zhang, Z | 1 |
| Araujo, JM; Gomez, AC; Pinto, JA; Raez, LE; Rolfo, C | 1 |
| Ahn, MJ; Barlesi, F; Chen, D; Chiu, CH; Cho, BC; Day, BM; De Braud, F; Doebele, RC; Drilon, A; Dziadziuszko, R; Farago, AF; Karapetis, CS; Krebs, MG; Li, YC; Lin, CC; Liu, SV; Patel, MR; Siena, S; Wilson, TR | 1 |
| Antoniou, M; Bennett, I; Blay, JY; Hong, D; Krebs, MG; Le Tourneau, C; Veronese, L | 1 |
| Delgado, J; Enzmann, H; Josephson, F; Melchiorri, D; Migali, C; Pean, E; Pignatti, F | 1 |
| Gao, Y; Gong, Y; Jiang, X; Li, J; Luo, Y; Xie, C; Zeng, Z; Zhang, J; Zhang, N | 1 |
| Frampton, JE | 1 |
| Ahn, MJ; Barlesi, F; Chen, D; Conley, A; Demetri, G; Doebele, R; Drilon, A; Kapre, A; McCallum, S; Osborne, S; Paz-Ares, L; Rolfo, C; Seto, T; Siena, S; Wolf, J | 1 |
| Beydoun, N; Cooper, W; Kasherman, L; Liu, Q; Lu, M; Lynch, J; Woodford, R | 1 |
| Chen, DH; Fonseca, M; Ghosh, AK; Walker, JM | 1 |
| Barlesi, F; Bennouna, J; Berard, H; Besse, B; Debieuvre, D; Gervais, R; Jacquot, S; Lacas, B; Lena, H; Mazières, J; Milleron, B; Molinier, O; Moreau, L; Morin, F; Moro-Sibilot, D; Petit, L; Pignon, JP; Ribassin-Majed, L; Soria, JC; Souquet, PJ; Zalcman, G | 1 |
| Besse, B; Bria, E; Facchinetti, F; Friboulet, L; Minari, R; Rossi, G; Soria, JC; Tiseo, M | 1 |
| Bang, YJ; Hamid, O; Kang, YK; Kim, TM; Michael, M; Park, YS; Raddad, E; Tate, SC; Thornton, D; Tie, J | 1 |
| Ai, J; Chen, H; Chen, X; Gao, Y; Geng, M; He, Y; Li, C; Liu, H; Peng, X; Wang, J; Wang, Y; Zheng, M; Zhu, W | 1 |
| Kang, MJ; Lee, JH; Yun, HH | 1 |
| Adjei, AA; Bahleda, R; Besse, B; Dy, GK; Ferte, C; Groen, HJM; Lin, W; Morrissey, K; Planchard, D; Schutzman, JL; Shankar, G; Soria, JC; Ware, J; Zhou, J | 1 |
| Liu, D; Ren, H; Sun, X; Wang, J; Wang, M; Xiao, G; Xu, C; Zhang, B; Zhang, J | 1 |
| Chorner, PM; Moorehead, RA | 1 |
| Arbour, KC; Riely, GJ | 1 |
| Burris, HA; Daniel, DB; Finney, L; Gian, VG; Greco, FA; Hainsworth, JD; Heymach, JV; Lipman, AJ; Shih, KC; Spigel, DR; Waterhouse, DM | 1 |
| Biemans, R; Bussink, J; Dubois, LJ; Meijer, TWH; Peeters, WJM; Span, PN; van Gisbergen, MW; Venhuizen, JH | 1 |
| Ak, G; Bozkaya, ÜF; Hamarat Şanlıer, Ş; Tanıyan, G; Ünal, A; Yıldırım, Y; Yıldız Türkyılmaz, G; Yılmaz, H | 1 |
| Chang, AC; Chen, G; Cheng, G; Hardy, M; Kalyanaraman, B; Kresty, L; Lee, Y; Myers, CR; Ouari, O; Pan, J; Weh, K; You, M; Zhang, Q; Zielonka, J; Zielonka, M | 1 |
| Ahn, JS; Ahn, MJ; Bae, YH; Ku, BM; Lee, KY; Lee, SH; Park, K; Sun, JM | 1 |
| Al-Salama, ZT; Keam, SJ | 1 |
| King, JW; Lee, SM | 1 |
| Beauchamp, EM; Getz, G; Gray, NS; Haddad, RI; Hammerman, PS; Hayes, DN; Jung, J; Liao, RG; Liu, Q; Meyerson, M; Pedamallu, CS; Pugh, TJ; Sivachenko, A; Tchaicha, J; Wilkerson, MD; Wong, KK | 1 |
| André, F; Ashworth, A; Bajrami, I; Dorvault, N; Elliott, R; Fontebasso, Y; Friboulet, L; Lord, CJ; Olaussen, KA; Postel-Vinay, S; Soria, JC | 1 |
| Bi, C; Credille, KM; Donoho, GP; Manro, JR; Peek, VL; Walgren, RA; Wijsman, JA; Wu, W; Yan, L; Yan, SB | 1 |
| Bian, XC; Feng, HL; Li, ZW; Liu, YQ; Liu, YY; Yang, ZL | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Arif, Q; Hasina, R; Husain, AN; Kawada, I; Mueller, J; Salgia, R; Smithberger, E; Vokes, EE | 1 |
| Bycott, P; Chen, C; Chmielowska, E; de Besi, P; Havel, L; Ingrosso, A; Kim, S; Olszanski, AJ; Popat, S; Sawrycki, P; Schiller, JH; Swieboda-Sadlej, A; Twelves, C; Williams, JA | 1 |
| Besse, B; Bosquee, L; Chouaid, C; Felip, E; Lechevalier, T; Lianes-Barragán, P; Mellemgaard, A; Ottesen, LH; Paul, EM; Reck, M; Ruiz-Soto, R; Scagliotti, GV; Sigal, E; von Pawel, J | 1 |
| Belani, CP; Bondarenko, IM; Bycott, P; Ingrosso, A; Kim, S; Niethammer, AG; Novello, S; Poltoratskiy, A; Scagliotti, GV; Tang, J; Yamamoto, N | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Carlson, DM; Horai, T; Horiike, A; Horinouchi, H; Kaneda, H; McKee, MD; Nakagawa, K; Nishio, M; Nokihara, H; Ohyanagi, F; Okabe, T; Tamura, T; Terashima, M; Xiong, H; Yamamoto, N | 1 |
| Bridges, KA; Buchholz, TA; Buser, CA; Liu, H; Meyn, RE; Toniatti, C | 1 |
| Dhruva, N; Grilley-Olson, J; Ivanova, A; Socinski, MA; Stinchcombe, TE; Villaruz, LC; Weiss, JM | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Axelrod, R; Barrios, CH; Belani, CP; Carlson, DM; Devanarayan, V; Gorbunova, VA; Kolman, P; Makhson, A; McKee, MD; McKeegan, EM; Owonikoko, TK; Pereira, JR; Pittman, KB; Qian, J; Qin, Q; Ramalingam, SS; Ricker, JL; Segalla, JG; Shtivelband, M; Soo, RA; Srkalovic, G | 1 |
| Han, S; Hyun, C; Jo, J; Kim, JH; Kim, JY; Kim, W; Kwon, J; Rhee, J | 1 |
| Bondarenko, IM; Bycott, P; Cebotaru, CL; Ingrosso, A; Kim, S | 1 |
| Baas, P; Blackhall, F; Cufer, T; Gaafar, R; Georgoulias, V; Hasan, B; Hennig, I; Menis, J; Montes, A; O'Brien, ME; Popat, S; Schmid-Bindert, G; Surmont, V; Woll, PJ | 1 |
| Choi, EY; Kim, S; Kwon, TK; Lee, J; Park, JW; Shin, KC | 1 |
| Kim, D; Kwon, A; Lee, BY; Min, KH; Nguyen, HK; Song, J; Suh, W; Yoo, J | 1 |
| Ansell, PJ; Bhathena, A; Carlson, DM; Chakravartty, A; Chan, S; Chandran, RK; Davis, G; Devanarayan, V; Dowell, BL; Gawel, SH; McKee, MD; McKeegan, EM; Ramalingam, SS; Ricker, JL | 1 |
| Bauer, TM; Chow-Maneval, E; Costa, DB; Drilon, A; Farago, AF; Hornby, Z; Iafrate, AJ; Jackman, D; Le, LP; Li, GG; Lim, JE; Liu, SV; Luo, D; Multani, PS; Muzikansky, A; Ou, SH; Patel, M; Shaw, AT; Zheng, Z | 1 |
| Bertino, E; Haglund, K; Haraldsdottir, S; Kaffenberger, B; Shah, MH | 1 |
| Ikezawa, Y; Mizugaki, H; Nishimura, M; Oizumi, S; Sakakibara-Konishi, J | 1 |
| Barr, M; Cuffe, S; Finn, S; Gately, K; Heavey, S; Leonard, N; McVeigh, N; Nicholson, S; O'Byrne, K; Ryan, R; Young, V | 1 |
| Amantea, MA; Chen, Y; Garrett, M; Ingrosso, A; Mould, DR; Pithavala, YK; Taylor, T | 1 |
| Bauer, S; Baumann, M; Engel, J; Ketzer, J; Keul, M; Lategahn, J; Mühlenberg, T; Rauh, D; Schultz-Fademrecht, C; Tomassi, S; Tumbrink, HL | 1 |
| Döme, B; Magyar, M | 1 |
| Bycott, P; Kim, S; Larson, T; Liau, K; Limentani, S; Olszanski, AJ; Ou, SH; Sandler, A; Schiller, JH; Vokes, E; von Pawel, J | 1 |
| Altorki, N; Bordogna, W; Heymach, JV; Nikolinakos, PG; Ottesen, LH; Rajagopalan, D; Tran, HT; Yan, S; Yankelevitz, D | 1 |
| Ratain, MJ | 1 |
| Altorki, N; Bauer, T; Felip, E; Grannis, FW; Guarino, MJ; Gurpide, A; Huff, A; Lane, ME; Lee, PC; Mitchell, JD; Ottesen, LH; Pass, H; Peylan-Ramu, N; Reeves, A; Roychowdhury, DF; Swann, RS; Tachdjian, S; Yankelevitz, DF | 1 |
| Besse, B; Carlson, DM; Gandara, DR; Goss, GD; Gupta, N; Hanna, NH; Hensing, T; Lee, C; Mazieres, J; Pradhan, R; Qian, J; Qin, Q; Ricker, JL; Salgia, R; Scappaticci, FA; Soo, RA; Tan, EH; Thertulien, R; Wertheim, M; Yang, JC | 1 |
| Bellenger, J; Shen, YZ; Wang, F; Zhang, LN; Zhang, XH; Zou, ZQ | 1 |
| Goozner, M | 1 |
| B Cohen, R; Olszanski, AJ; Patson, B | 1 |
| Albert, DH; Day, M; Fox, GB; Hickson, JA; Luo, Y; Mudd, SR; Refici-Buhr, M; Reuter, DR; Tapang, P; Voorbach, MJ | 1 |
| Arriola, E; Cohen, RB; De Castro Carpeño, J; Herbst, RS; Kim, S; Kozloff, MF; Krzakowski, M; Martin, LP; Olszanski, AJ; Rado, TA; Rosbrook, B; Samuel, TA; Tarazi, J; Tortorici, M | 1 |
| Amler, LC; Brachmann, RK; Fridlyand, J; Friedman, LS; Hampton, GM; Haverty, PM; Huw, L; Koeppen, H; Lackner, MR; Mohan, S; O'Brien, C; Pandita, A; Ross, L; Sampath, D; Shames, DS; Spoerke, JM | 1 |
| Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Ferretti, G; Papaldo, P | 1 |
| Buccheri, G; Ferrigno, D | 1 |
| Nardini, S | 1 |
| Evans, G; McCunniff, AJ; Paggiarino, DA; Scarantino, CW; Young, CW | 1 |
| Berni, F; Calzavara, MP; Cattaneo, MT; D'Adda, D; Filipazzi, V; Frontini, L; Isa, L; Legnani, W; Rho, B; Scapaticci, R | 1 |
| Buccheri, G; Ferrigno, D; Rosso, A | 1 |
| Brancaccio, L; Carnicelli, P; Cioffi, R; Comella, P; De Cataldis, G; Ianniello, GP; Lombardi, A; Maiorino, A; Scarpati, MD; Tinessa, V | 1 |
| Bianco, A; Bilancia, D; Carpagnano, F; Cioffi, R; Comella, G; Comella, P; De Cataldis, G; De Lena, M; Di Rienzo, G; Frasci, G; Lorusso, V; Maiorino, L; Manzione, L; Natale, M; Nicolella, G; Pacilio, C; Panza, N | 1 |
| Christoffel, V; Gatzemeier, U; Lücker, PW; Picollo, R; Toomes, H; Ulmer, J | 1 |
| Contu, A; Deriu, A; Olmeo, NA; Ortu, S; Paga, C; Pani, P | 1 |
| Cionini, L | 1 |
| Cavalli, F; Gatzemeier, U; Häussinger, K; Kaukel, E; Koschel, G; Martinelli, G; Neuhauss, R; von Pawel, J | 1 |
| Hardy, JR; Jones, AL; Newell, DR; Smith, IE | 1 |
| Canova, N; Casadio, M; Guaraldi, M; Lelli, G; Pannuti, F | 1 |
| Ciottoli, GB; De Gregorio, M; Kokron, O; Maca, S | 1 |
| Bagatella, M; Bonardi, G; Calciati, A; Donadio, M; Giaccone, G; Maestroni, F | 1 |
| Albera, C; Gozzelino, F; Pescetti, G; Scagliotti, GV | 1 |
| Ambesi Impiombato, F; Antilli, A; Ciottoli, GB; De Gregorio, M; Del Vecchio, MR; Gallo-Curcio, C; Rinaldi, M; Tonachella, R; Tropea, F; Verturo, I | 1 |
18 review(s) available for indazoles and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Entrectinib, a new multi-target inhibitor for cancer therapy.
Topics: Adult; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases | 2022 |
A review on synthetic strategy, molecular pharmacology of indazole derivatives, and their future perspective.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms | 2022 |
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Topics: Animals; Benzamides; Carcinoma, Non-Small-Cell Lung; Disease Progression; Gene Fusion; Gene Rearrangement; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2020 |
Evaluating entrectinib as a treatment option for non-small cell lung cancer.
Topics: Administration, Oral; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Treatment Outcome | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins | 2021 |
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearr
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Gene Fusion; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptors, Amino Acid | 2021 |
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptor, trkA | 2021 |
Disseminated intravascular coagulation complicating diagnosis of ROS1-mutant non-small cell lung cancer: A case report and literature review.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Disseminated Intravascular Coagulation; Female; Humans; Indazoles; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2021 |
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Topics: Aminopyridines; Anilides; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Diagnostic Techniques; Oncogene Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Sulfones | 2017 |
Entrectinib: First Global Approval.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors | 2019 |
Axitinib for the treatment of advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Imidazoles; Indazoles; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival Rate | 2013 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |
Pharmacokinetic evaluation of axitinib.
Topics: Animals; Axitinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Pancreatic Neoplasms; Protein Kinase Inhibitors; Thyroid Neoplasms | 2012 |
Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Humans; Indazoles; Lung Neoplasms; Male; Ovarian Neoplasms; Safety | 2003 |
Non small cell lung cancer and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Fluorouracil; Humans; Indazoles; Lomustine; Lung Neoplasms; Methotrexate; Neoplasm Staging; Treatment Outcome | 1994 |
Radiotherapy plus lonidamine in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms | 1991 |
35 trial(s) available for indazoles and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Child; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Young Adult | 2022 |
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Survival Rate; Treatment Outcome | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rati
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; DNA Repair Enzymes; Germ-Line Mutation; Humans; Indazoles; Lung Neoplasms; Mesothelioma, Malignant; Mutation; Piperidines; Pleural Neoplasms; Prognosis; Prospective Studies | 2021 |
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications.
Topics: Adult; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms | 2021 |
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Patient Reported Outcome Measures; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Quality of Life | 2021 |
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2017 |
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Receptors, Fibroblast Growth Factor; Stomach Neoplasms; Young Adult | 2017 |
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-s
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Treatment Outcome | 2017 |
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Progression-Free Survival; Proteomics; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2018 |
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2014 |
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Pyrimidines; Sulfonamides; Survival Rate | 2013 |
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Glutamates; Guanine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pemetrexed; Vascular Endothelial Growth Factor A | 2014 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Japan; Leukopenia; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Thrombocytopenia; Tumor Burden | 2014 |
A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrimidines; Sulfonamides; Treatment Outcome | 2014 |
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phenylurea Compounds; Receptors, Platelet-Derived Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2015 |
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2015 |
Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Diagnosis, Differential; Femoral Neoplasms; Fracture Fixation, Intramedullary; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Middle Aged; Oximes; Pyrimidines; Radiodermatitis; Radiotherapy, Adjuvant; Sulfonamides | 2016 |
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2009 |
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Topics: Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Cytokines; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrimidines; Sulfonamides | 2010 |
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Fatigue; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypertension; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrimidines; Sulfonamides; Treatment Outcome | 2010 |
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Indazoles; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Treatment Outcome | 2012 |
A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG)
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Indazoles; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Survival Analysis | 1994 |
A prospective randomized comparison of radiation therapy plus lonidamine versus radiation therapy plus placebo as initial treatment of clinically localized but nonresectable nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Double-Blind Method; Humans; Indazoles; Lung Neoplasms; Male; Prospective Studies; Radiation-Sensitizing Agents | 1994 |
A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Tolerance; Female; Follow-Up Studies; Humans; Indazoles; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoplasm Staging; Pilot Projects; Remission Induction; Survival Rate | 1993 |
Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vindesine | 1996 |
Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quality of Life; Vinblastine; Vindesine; Vinorelbine | 1999 |
Lonidamine in non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Humans; Indazoles; Liver; Lung Neoplasms; Male; Middle Aged | 1991 |
Phase III trial with and without lonidamine in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Time Factors; Vindesine | 1991 |
Lonidamine versus polychemotherapy in advanced non-small-cell lung cancer. A preliminary analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Mitomycins; Pyrazoles; Vinblastine | 1989 |
Chemotherapy/radiation therapy plus/minus lonidamine in the treatment of non-small cell lung cancer (limited disease): preliminary results.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Pyrazoles; Random Allocation; Time Factors | 1988 |
52 other study(ies) available for indazoles and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism.
Topics: Animals; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Models, Biological; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Rats | 2022 |
Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
Topics: Adult; Benzamides; Carcinoma, Non-Small-Cell Lung; Child; Humans; Indazoles; Lung Neoplasms; Neoplasms, Second Primary; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases | 2022 |
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
Topics: Adult; Benzamides; Carcinoma, Non-Small-Cell Lung; Child; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2022 |
Effectiveness of crizotinib versus entrectinib in
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Treatment Outcome | 2022 |
Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Genomics; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2022 |
Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation Tolerance; Radiation-Sensitizing Agents | 2022 |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Topics: Aminopyridines; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Drug Development; Drug Resistance, Neoplasm; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Membrane Glycoproteins; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Receptor, trkB | 2019 |
Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2020 |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Gene Fusion; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Time Factors | 2020 |
YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Endocytosis; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lung Neoplasms; Protein Transport; Proteolysis | 2020 |
Structural Insights into the Molecular Design of ROS1 Inhibitor for the Treatment of Non-Small Cell Lung Cancer (NSCLC).
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Design; Humans; Indazoles; Lung Neoplasms; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2021 |
Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Feedback, Physiological; Gefitinib; Gene Knockdown Techniques; Humans; Indazoles; Lung Neoplasms; Male; Mice; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Topics: Adenosine; Adult; Aged; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Protein Kinase Inhibitors; Pyridones; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction | 2020 |
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Young Adult | 2021 |
PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
Topics: Animals; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemokine CCL5; Chemokine CXCL10; Chemoradiotherapy; DNA Breaks, Double-Stranded; Female; Fluorescent Antibody Technique; Genes, erbB-1; Humans; Immune System; Immunocompetence; Indazoles; Interferon Regulatory Factor-3; Interferon-beta; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Membrane Proteins; Mice; Mice, Inbred C57BL; Mutation; Nuclear Proteins; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Serine-Threonine Kinases; Radiation Tolerance; Radiation-Sensitizing Agents; Real-Time Polymerase Chain Reaction; TATA Box Binding Protein-Like Proteins; Tumor Stem Cell Assay | 2021 |
Entrectinib-related myocarditis in a young female patient with metastatic non-small cell lung cancer.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indazoles; Lung Neoplasms; Middle Aged; Myocarditis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2021 |
Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Databases, Chemical; Drug Design; Drug Screening Assays, Antitumor; Female; Heterografts; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasm Transplantation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Rats, Sprague-Dawley; Signal Transduction; Stereoisomerism; Structure-Activity Relationship | 2017 |
KRIBB11 accelerates Mcl-1 degradation through an HSF1-independent, Mule-dependent pathway in A549 non-small cell lung cancer cells.
Topics: Aminopyridines; Apoptosis; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Heat Shock Transcription Factors; HSP70 Heat-Shock Proteins; Humans; Indazoles; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Endopeptidase Complex; Proteolysis; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases | 2017 |
CCAT1 stimulation of the symmetric division of NSCLC stem cells through activation of the Wnt signalling cascade.
Topics: Axitinib; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Division; Genetic Therapy; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; MicroRNAs; Neoplastic Stem Cells; Prognosis; RNA, Long Noncoding; Wnt Signaling Pathway | 2018 |
A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 2; Down-Regulation; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Indazoles; Lung Neoplasms; Pyridines | 2018 |
Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indazoles; Lung Neoplasms; Proteomics; Pyrimidines; Sulfonamides | 2018 |
Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Radiation; Enzyme Inhibitors; Glucose; Glutaminase; Glutamine; Glycolysis; Humans; Indazoles; Lung Neoplasms; Radiation Tolerance; X-Rays | 2018 |
Development of Ultrasound-Triggered and Magnetic-Targeted Nanobubble System for Dual-Drug Delivery.
Topics: A549 Cells; Administration, Inhalation; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Compounding; Drug Delivery Systems; Ferrosoferric Oxide; Humans; Indazoles; Injections, Intralesional; Liposomes; Lung Neoplasms; Magnetic Phenomena; Mice; Nanoparticles; Nebulizers and Vaporizers; Pemetrexed; Pyrimidines; Sulfonamides; Tissue Distribution; Tumor Burden; Ultrasonic Waves; Xenograft Model Antitumor Assays | 2019 |
Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis.
Topics: Animals; Antineoplastic Agents; Autophagy; Brain Neoplasms; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Electron Transport Complex I; Electron Transport Complex II; Female; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Mitochondria; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2019 |
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras) | 2020 |
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.
Topics: Animals; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Dimerization; Humans; Indazoles; Interleukin-3; Ligands; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Protein Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides | 2013 |
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; High-Throughput Screening Assays; Humans; Indazoles; Lung Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Isoforms; Rad51 Recombinase; RNA Interference; RNA, Small Interfering | 2013 |
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Gene Expression; Hepatocyte Growth Factor; Humans; Indazoles; Lung Neoplasms; Mice; Neoplasm Metastasis; Niacinamide; Oncogene Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-met; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
[Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
Topics: Apoptosis; bcl-2-Associated X Protein; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; Humans; Indazoles; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Signal Transduction; Sulfonamides | 2013 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
Topics: Amino Acid Sequence; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Enzyme Activation; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Indazoles; Lung Neoplasms; Mice; Niacinamide; Peptides; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; Female; Histones; Humans; Hydrogen Peroxide; Indazoles; Lung Neoplasms; Male; Microscopy, Fluorescence; Oxidants; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Rad51 Recombinase; Radiation-Sensitizing Agents; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2014 |
Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Pyrimidines; Republic of Korea; Sulfonamides; Treatment Outcome | 2016 |
Treatment with a Small Synthetic Compound, KMU-193, induces Apoptosis in A549 Human Lung Carcinoma Cells through p53 Up-Regulation.
Topics: Acetamides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Flow Cytometry; Humans; Indazoles; Lung Neoplasms; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2015 |
Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases.
Topics: Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Molecular Docking Simulation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Structure-Activity Relationship; Sulfonamides; Vascular Endothelial Growth Factor A | 2015 |
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Indazoles; Keratin-19; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phenylurea Compounds | 2015 |
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Cohort Studies; Female; Gene Rearrangement; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Receptor, trkA | 2015 |
Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lung Neoplasms; Mice, Nude; Molecular Targeted Therapy; Oligopeptides; Receptors, Notch; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2017 |
In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
Topics: A549 Cells; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azetidines; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Lung Neoplasms; Male; MAP Kinase Kinase Kinases; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2016 |
Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Non-Small-Cell Lung; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Smoking | 2016 |
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indazoles; Lung; Lung Neoplasms; Mice; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors | 2017 |
Bar the windows but open the door to randomization.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Sulfonamides; Treatment Outcome | 2010 |
The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells.
Topics: Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Humans; Indazoles; Lung Neoplasms; Mitogen-Activated Protein Kinases; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2012 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Fluorodeoxyglucose F18; Humans; Indazoles; Lung Neoplasms; Mice; Mice, SCID; Phenylurea Compounds; Positron-Emission Tomography; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2012 |
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; DNA Copy Number Variations; DNA Mutational Analysis; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Indazoles; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Transcriptome; Xenograft Model Antitumor Assays | 2012 |
Cisplatin plus epirubicin and etoposide followed by irradiation plus lonidamine in stage III nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged | 1993 |
Single- and multiple dose pharmacokinetics of lonidamine in patients suffering from non-small-cell lung cancer.
Topics: Adult; Aged; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, Gas; Chromatography, High Pressure Liquid; Female; Humans; Indazoles; Liver; Lung Neoplasms; Male; Middle Aged | 1991 |
Clinical study and pharmacokinetics of lonidamine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged | 1991 |
A phase II study on lonidamine combined with cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma (NSCBC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Remission Induction | 1990 |
Phase II study of lonidamine in non-small cell lung cancer: final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrazoles | 1990 |
Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indazoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrazoles | 1989 |